Monopar Therapeutics prices $19.2M public stock offering at $16.25 per share

Monopar Therapeutics

Gross proceeds ~$19.2M from offering of up to 1,181,540 shares at $16.25/share.
Participating investors include Janus Henderson, RA Capital Management, L.P.
Net proceeds to be used for R&D, clinical trials, manufacture, and working capital.
Offering closed October 30, 2024; Rodman & Renshaw acted as placement agent.
Placement agent fee is 7.0% of gross proceeds plus expense reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.